MX2020003706A - Aminoimidazopiridazinas como inhibidores de cinasa. - Google Patents

Aminoimidazopiridazinas como inhibidores de cinasa.

Info

Publication number
MX2020003706A
MX2020003706A MX2020003706A MX2020003706A MX2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A
Authority
MX
Mexico
Prior art keywords
aminoimidazopyridazines
kinase inhibitors
kinase
inhibitors
empty
Prior art date
Application number
MX2020003706A
Other languages
English (en)
Spanish (es)
Inventor
Carolyn Diane Dzierba
Amy C Hart
William J Pitts
Steven H Spergel
Guanglin Luo
Jianliang Shi
John E Macor
Michael E Mertzman
Jason M Guernon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020003706A publication Critical patent/MX2020003706A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2020003706A 2017-10-30 2018-10-29 Aminoimidazopiridazinas como inhibidores de cinasa. MX2020003706A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578607P 2017-10-30 2017-10-30
US201862626853P 2018-02-06 2018-02-06
PCT/US2018/057968 WO2019089442A1 (en) 2017-10-30 2018-10-29 Aminoimidazopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2020003706A true MX2020003706A (es) 2020-07-22

Family

ID=64332173

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003706A MX2020003706A (es) 2017-10-30 2018-10-29 Aminoimidazopiridazinas como inhibidores de cinasa.

Country Status (23)

Country Link
US (1) US11440913B2 (https=)
EP (1) EP3704118B1 (https=)
JP (1) JP7228586B2 (https=)
KR (1) KR102662197B1 (https=)
CN (1) CN111566103B (https=)
AU (1) AU2018361249B2 (https=)
BR (1) BR112020007557A2 (https=)
CA (1) CA3080402A1 (https=)
CY (1) CY1124984T1 (https=)
DK (1) DK3704118T3 (https=)
ES (1) ES2905948T3 (https=)
HR (1) HRP20220297T1 (https=)
HU (1) HUE058292T2 (https=)
IL (1) IL274207B2 (https=)
LT (1) LT3704118T (https=)
MX (1) MX2020003706A (https=)
PL (1) PL3704118T3 (https=)
PT (1) PT3704118T (https=)
RS (1) RS62974B1 (https=)
SG (1) SG11202003824PA (https=)
SI (1) SI3704118T1 (https=)
SM (1) SMT202200087T1 (https=)
WO (1) WO2019089442A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47460A (fr) 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
CN112262139B (zh) 2018-01-26 2023-07-25 百时美施贵宝公司 作为激酶抑制剂的氨基吡咯并三嗪
AU2019339355A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
ES2969756T3 (es) * 2019-10-03 2024-05-22 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas
WO2021168521A1 (en) * 2020-02-27 2021-09-02 Anaxis Pharma Pty Ltd Inhibitors of necroptosis
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
CN117120052A (zh) * 2020-10-13 2023-11-24 约翰斯·霍普金斯大学 取代的4-([1,2,4]三唑并[1,5-a]吡啶-6-基)噻吩-2-甲酰胺衍生物及其用途
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
CN120530112A (zh) * 2022-12-30 2025-08-22 广州市联瑞制药有限公司 双环类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
JP5589003B2 (ja) * 2009-02-04 2014-09-10 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 脂質障害のような代謝疾患の処置のために有用な[1,3]オキサジン−2−オンの誘導体
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
WO2014081756A1 (en) 2012-11-20 2014-05-30 Biogen Idec Ma Inc. S1p and/or atx modulating agents
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
SG11201509351UA (en) 2013-06-10 2015-12-30 Bayer Pharma AG Novel compounds for the treatment of cancer
RU2017109122A (ru) 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
SG11201809693SA (en) 2016-05-05 2018-11-29 Lysosomal Therapeutics Inc SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
MA47460A (fr) * 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
CN112262139B (zh) 2018-01-26 2023-07-25 百时美施贵宝公司 作为激酶抑制剂的氨基吡咯并三嗪
AU2019339355A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
EP3877371A4 (en) * 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF

Also Published As

Publication number Publication date
HUE058292T2 (hu) 2022-07-28
CA3080402A1 (en) 2019-05-09
ES2905948T3 (es) 2022-04-12
RS62974B1 (sr) 2022-03-31
CY1124984T1 (el) 2023-01-05
CN111566103B (zh) 2023-06-23
LT3704118T (lt) 2022-02-25
SG11202003824PA (en) 2020-05-28
PL3704118T3 (pl) 2022-04-04
AU2018361249A1 (en) 2020-06-11
US20200277296A1 (en) 2020-09-03
PT3704118T (pt) 2022-02-14
KR20200078591A (ko) 2020-07-01
AU2018361249B2 (en) 2022-08-25
KR102662197B1 (ko) 2024-04-29
CN111566103A (zh) 2020-08-21
SI3704118T1 (sl) 2022-04-29
BR112020007557A2 (pt) 2020-09-24
HRP20220297T1 (hr) 2022-05-13
SMT202200087T1 (it) 2022-03-21
JP2021501179A (ja) 2021-01-14
WO2019089442A1 (en) 2019-05-09
EP3704118A1 (en) 2020-09-09
EP3704118B1 (en) 2022-01-12
IL274207B2 (en) 2023-04-01
US11440913B2 (en) 2022-09-13
JP7228586B2 (ja) 2023-02-24
WO2019089442A8 (en) 2019-06-27
DK3704118T3 (da) 2022-03-14
IL274207A (en) 2020-06-30
IL274207B (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
MX2020003430A (es) Derivados de 1-bencil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de proteasa de virus de inmunodeficiencia humana.
ZA201905811B (en) Novel inhibitors
MX2020004287A (es) Procesamiento de biomasa.
MX2020003760A (es) Formulaciones de niraparib.
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11202100525SA (en) Pyrrolopyrimidine itk inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2017000363A (es) Inhibicion de la via de notch.
MX2020004424A (es) Formulacion aerosolizable.
MX2020003439A (es) Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1).
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2020004455A (es) Derivados de pirrolopirazina como inhibidores de integrina alfa v.
MX2020003440A (es) Red de seguridad.
MX2020002908A (es) Composicion acuosa de polimeros.
MX2020003611A (es) Metodos de refuerzo del pozo.
MX2020003578A (es) Sal de edaravone.
IL252986A0 (en) 5,3-diaminopyrazole kinase inhibitors
MX2020003487A (es) Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos.
MX2020003703A (es) Composiciones de sabor.
MX2020004048A (es) Formas cristalinas de lenalidomida.
GB201807845D0 (en) Kinase Inhibitors
MX2020004664A (es) Dispositivo generador de humo mejorado.